First-line therapy with palbociclib in patients with advanced HR⁺/HER2^- breast cancer: The real-life study PALBOSPAIN.

ABSTRACT:

Purpose

To evaluate the efficacy and safety of first-line therapy with palbociclib in a Spanish cohort treated after palbociclib approval.

Methods

PALBOSPAIN is an observational, retrospective, multicenter study evaluating real-world patterns and outcomes with 1 L palbociclib in men and women (any menopausal status) with advanced HR⁺/HER2- BC diagnosed between November 2017 and November 2019. The primary endpoint was real-world progression-free survival (rw-PFS). Secondary endpoints included overall survival (OS), the real-world response rate (rw-RR), the clinical benefit rate, palbociclib dose reduction, and safety.

Results

A total of 762 patients were included. The median rw-PFS and OS were 24 months (95% CI 21-27) and 42 months (40-not estimable [NE]) in

SUBMITTER: Martinez-Janez N 

PROVIDER: S-EPMC11182794 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature